Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGT007 in Recurrent/Refractory Gastrointestinal Malignancies
NCT06645301Phase 1Not yet recruiting
- Sponsor
- Biosyngen
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
01
Overview
Phase 1, open-label, single-arm trial of BGT007 in colorectal cancer (CRC) and pancreatic cancer (PC), sponsored by Biosyngen. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
BGT007
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06645301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06645301.